Isothiocyanates Potentiate Tazemetostat-Induced Apoptosis by Modulating the Expression of Apoptotic Genes, Members of Polycomb Repressive Complex 2, and Levels of Tri-Methylating Lysine 27 at Histone 3 in Human Malignant Melanoma Cells

Authors

Ioannis Anestopoulos, The Cyprus Institute of Neurology & Genetics
Ioannis Paraskevaidis, The Cyprus Institute of Neurology & Genetics
Sotiris Kyriakou, The Cyprus Institute of Neurology & Genetics
Lambrini E. Giova, The Cyprus Institute of Neurology & Genetics
Dimitrios T. Trafalis, National & Kapodistrian University of Athens
Sotiris Botaitis, Democritus University of Thrace
Rodrigo Franco, University of Nebraska - LincolnFollow
Aglaia Pappa, Democritus University of Thrace
Mihalis L. Panayiotidis, The Cyprus Institute of Neurology & Genetics

Document Type

Article

Date of this Version

2-23-2024

Citation

Anestopoulos, I.; Paraskevaidis, I.; Kyriakou, S.; Giova, L.E.; Trafalis, D.T.; Botaitis, S.; Franco, R.; Pappa, A.; Panayiotidis, M.I. Isothiocyanates Potentiate Tazemetostat-Induced Apoptosis by Modulating the Expression of Apoptotic Genes, Members of Polycomb Repressive Complex 2, and Levels of Tri-Methylating Lysine 27 at Histone 3 in Human Malignant Melanoma Cells. Int. J. Mol. Sci. 2024, 25, 2745. https://doi.org/10.3390/ ijms25052745

Comments

Open access.

Abstract

In this study, we utilized an in vitro model consisting of human malignant melanoma as well as non-tumorigenic immortalized keratinocyte cells with the aim of characterizing the therapeutic effectiveness of the clinical epigenetic drug Tazemetostat alone or in combination with various isothiocyanates. In doing so, we assessed markers of cell viability, apoptotic induction, and expression levels of key proteins capable of mediating the therapeutic response. Our data indicated, for the first time, that Tazemetostat caused a significant decrease in viability levels of malignant melanoma cells in a dose- and time-dependent manner via the induction of apoptosis, while non-malignant keratinocytes were more resistant. Moreover, combinatorial treatment protocols caused a further decrease in cell viability, together with higher apoptotic rates. In addition, a significant reduction in the Polycomb Repressive Complex 2 (PRC2) members [e.g., Enhancer of Zeste Homologue 2 (EZH2), Embryonic Ectoderm Development (EED), and suppressor of zeste 12 (SUZ12)] and tri-methylating lysine 27 at Histone 3 (H3K27me3) protein expression levels was observed, at least partially, under specific combinatorial exposure conditions. Reactivation of major apoptotic gene targets was determined at much higher levels in combinatorial treatment protocols than Tazemetostat alone, known to be involved in the induction of intrinsic and extrinsic apoptosis. Overall, we developed an optimized experimental therapeutic platform aiming to ensure the therapeutic effectiveness of Tazemetostat in malignant melanoma while at the same time minimizing toxicity against neighboring non-tumorigenic keratinocyte cells.